uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för radiologi, onkologi och strålningsvetenskap, Enheten för biomedicinsk strålningsvetenskap. (Tolmachev)
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för radiologi, onkologi och strålningsvetenskap, Enheten för biomedicinsk strålningsvetenskap. (Tolmachev)
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för radiologi, onkologi och strålningsvetenskap, Enheten för biomedicinsk strålningsvetenskap. (Tolmachev)
Vise andre og tillknytning
2014 (engelsk)Inngår i: European Journal of Medicinal Chemistry, ISSN 0223-5234, E-ISSN 1768-3254, Vol. 87, s. 519-528Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Affibody molecules constitute a class of small (7 kDa) scaffold proteins that can be engineered to have excellent tumor targeting properties. High reabsorption in kidneys complicates development of affibody molecules for radionuclide therapy. In this study, we evaluated the influence of the composition of cysteine-containing C-terminal peptide-based chelators on the biodistribution and renal retention of 188Re-labeled anti-HER2 affibody molecules. Biodistribution of affibody molecules containing GGXC or GXGC peptide chelators (where X is G, S, E or K) was compared with biodistribution of a parental affibody molecule ZHER2:2395 having a KVDC peptide chelator. All constructs retained low picomolar affinity to HER2-expressing cells after labeling. The biodistribution of all 188Re-labeled affibody molecules was in general comparable, with the main observed difference found in the uptake and retention of radioactivity in excretory organs. The 188Re-ZHER2:V2 affibody molecule with a GGGC chelator provided the lowest uptake in all organs and tissues. The renal retention of 188Re-ZHER2:V2 (3.1 ± 0.5 %ID/g at 4 h after injection) was 55-fold lower than retention of the parental 188Re-ZHER2:2395 (172 ± 32 %ID/g). We show that engineering of cysteine-containing peptide-based chelators can be used for significant improvement of biodistribution of 188Re-labeled scaffold proteins, particularly reduction of their uptake in excretory organs.

sted, utgiver, år, opplag, sider
2014. Vol. 87, s. 519-528
Emneord [en]
Rhenium-188; Affibody; HER2; Peptide-based chelator; Biodistribution; Radionuclide therapy
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-235383DOI: 10.1016/j.ejmech.2014.09.082ISI: 000363431300049PubMedID: 25282673OAI: oai:DiVA.org:uu-235383DiVA, id: diva2:759949
Tilgjengelig fra: 2014-11-01 Laget: 2014-11-01 Sist oppdatert: 2017-12-05bibliografisk kontrollert
Inngår i avhandling
1. Development of Affibody molecules for radionuclide molecular imaging and therapy of cancer
Åpne denne publikasjonen i ny fane eller vindu >>Development of Affibody molecules for radionuclide molecular imaging and therapy of cancer
2016 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

Affibody molecules are a promising class of scaffold-based targeting proteins for radionuclide-based imaging and therapy of cancer. This thesis work is based on 5 original research articles (papers I-V), which focus on optimization of molecular design of HER2-binding Affibody variants for high contrast imaging of this predictive biomarker as well as development of Affibody molecules suitable for radionuclide-based targeted therapies. 

Papers I and II were dedicated to evaluation of the influence of the macrocyclic chelator DOTA positioning at N-terminus, in the middle of helix-3 and at C terminus of a synthetic Affibody molecule, ZHER2:S1. These synthetic variants were labelled with different radionuclides i.e. 111In and 68Ga to study also the effect of different labels on their biodistribution properties.

In paper III a 2-helix variant, Z342min, was developed using native ligation cyclization to cross-link helices one and two resulting in a stable 2-helix scaffold and characterized in vivo. This study was performed with the aim to obtain structure-properties relationship for development of smaller Affibody molecules.  

Papers IV and V were devoted to development of therapeutic strategies. In paper IV, a series of peptide based chelators was investigated for labelling of Affibody molecules with 188Re to provide low renal retention. In paper V, a pretargeting approach using peptide nucleic acid was investigated. These studies were performed with the aim to overcome the high renal retention of Affibody molecules when labelled with residualizing therapeutic radionuclides. Otherwise, the particle emitting radiometals could damage the kidneys more than the tumours.

The results obtained for anti-HER2 Affibody molecules summarized in this thesis might be of importance for the development of other scaffold protein based targeting agents.

 

sted, utgiver, år, opplag, sider
Uppsala: Acta Universitatis Upsaliensis, 2016. s. 71
Serie
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1237
Emneord
Affibody molecules, HER2, Molecular imaging, Radionuclide targeted therapy, Radionuclide molecular imaging, Labeling chemistry
HSV kategori
Forskningsprogram
Biomedicinsk strålningsvetenskap
Identifikatorer
urn:nbn:se:uu:diva-298740 (URN)978-91-554-9624-1 (ISBN)
Eksternt samarbeid:
Disputas
2016-09-24, Fåhraeus Hall, Dag Hammarskjölds väg 20, Uppsala, 09:30 (engelsk)
Opponent
Veileder
Tilgjengelig fra: 2016-08-31 Laget: 2016-07-06 Sist oppdatert: 2016-09-05

Open Access i DiVA

fulltext(1744 kB)420 nedlastinger
Filinformasjon
Fil FULLTEXT02.pdfFilstørrelse 1744 kBChecksum SHA-512
f91fb786a32309d7acb2f0fdd607994b04b7af9e355b8423b63e52612618afe808c27196748a3d7a10e2fa8ed7a59aa0dc6fdb4fdc001aad2792b3abd3ce4d48
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Altai, MohamedHonarvar, HadisStrand, JoannaVarasteh, ZohrehRosestedt, MariaOrlova, AnnaSandström, MattiasTolmachev, Vladimir

Søk i DiVA

Av forfatter/redaktør
Altai, MohamedHonarvar, HadisStrand, JoannaVarasteh, ZohrehRosestedt, MariaOrlova, AnnaSandström, MattiasTolmachev, Vladimir
Av organisasjonen
I samme tidsskrift
European Journal of Medicinal Chemistry

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 420 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 1439 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf